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Background: Allogeneic hematopoietic stem cell trans-
plantation (AHSCT) is a common treatment modality for
patients (pts) with hematological disorders. We present
a retrospective review of the incidence and impact on
outcomes of central nervous system complications (CNSCs)
in a cohort of pts with hematological disorders undergoing
AHSCT, treated at a single institution.
Methods: 351 pts with hematological disorders who
received AHSCT between 2002 and 2011 at an academic
medical center were identiﬁed. Events that were considered
CNSCs included seizures, transient ischemic attack, intra-
cranial hemorrhage, ischemic stroke, subarachnoid hemor-
rhage, subdural hematoma, meningitis, and posterior
reversible encephalopathy syndrome (PRES). Data were ob-
tained from a review of the databases and medical records.
Patient-, disease- and transplant-related characteristics
were compared between pts with or without CNSCs.
Cumulative incidence of having CNSCs were estimated using
death as competing risk. Multivariate Cox proportional
hazard regression analysis was used to compare the risk of
mortality between pts with or without CNSCs while adjust-
ing for prognostic factors. Prognostic factors considered
included: age, sex, disease type, disease stage at transplant,
donor-recipient sex-match, cmv status, type of transplant,
level of antigen matching, graft type, year of transplant, use
of total body irradiation, and prior exposure to cytarabine or
cranial irradiation.
Results: Of the 351 pts identiﬁed, forty-ﬁve pts developed
CNSCs (12.8%). No differences in patient-, disease- and
transplant-related characterisitcs were noted between those
with or without CNSCs. The 100-day cumulative incidence of
CNSCs was 8% (95% conﬁdence interval [CI] 8-15%). The most
commonly observed CNSCs included: PRES 18 (40%), stroke
or TIA 11 (24%), seizures 9 (20%), and infection 4 (9%). In
univariate analysis, there was a difference in overall survival
(OS) according to CNSCs (log-rank P ¼ .0002). The OS at 5
years for pts with CNSCs was 14% (3-32) vs. 44% for pts
without CNSCs (P-value 0.0004). In multivariate analysis, the
risk of mortality for pts with CNSCs after AHSCT
was signiﬁcantly higher, hazard ratio (HR) 1.56 (95% CI1.03 e 2.36, P ¼ .04) compared to pts without CNSCs. Other
prognostic factors identiﬁed included: sex, disease type,
disease stage at transplant, level of antigen matching. Inter-
estingly, prior history of high dose cytarabine was also
associated with higher mortality, HR 2.19 (95% CI 1.51e3.18),
P < .0001.
Conclusion: The incidence of CNSCs after AHSCT is associ-
ated with reduced survival. Identifying pts at risk, moni-
toring, early identiﬁcation, and treatment for CNSCs post
AHSCT is needed to help alter the negative impact on out-
comes.
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Background: There is a paucity of knowledge regarding the
incidence and predictors of late-occurring cirrhosis that may
be due to early post-HCT hepatic complications or late-
occurring risk factors such as iron overload, chronic GvHD, or
persistent infectious hepatitis in HCT survivors; furthermore,
there is limited information regarding the epidemiology of
cirrhosis in HCT survivors after the implementation of
universal blood product screening for Hepatitis C in 1992.
Methods: Individuals with late-occurring (1 year post-
HCT) cirrhosis, utilizing World Health Organization criteria,
were selected from 1+year survivors of allogeneic HCT per-
formed at a single institution between 1976 and 2007. The
National Hospital Discharge Survey was used to compare the
HCT cohort with age-, sex-, and HCT year-speciﬁc rates of
cirrhosis in the general population. Cox proportional hazards
regression analysis was used to calculate relative risk (RR)
estimates and 95% conﬁdence intervals (CI), adjusted for
relevant covariates.
Results: Thirty nine cases of cirrhosis were identiﬁed in
a cohort of 1,737 HCT survivors, followed for a median of 6.1y
(1-33). Median age at HCT: 33.8y (0.6-74.9); median time to
cirrhosis: 6.0y (1-25.6); 64% were male; 41% Hispanic; 62%
underwent HCT<1992; Hepatitis C infection was present in
56.4%. Cumulative incidence of cirrhosis was 1.6% at 10 yrs
and 4.6% at 20 yrs post-HCT. The cohort was at a 15-fold
increased risk of cirrhosis (standardized incidence ratio [SIR]
15.0, CI:10.8-20.3) when compared to the general pop-
ulation. The risk was highest for patients who underwent
HCT<1992 (SIR¼27.9, CI:18.2-40.6); the risk remained
elevated among those transplanted 1992 (SIR¼8.7, CI:5.0-
13.8). Absolute excess risk for the entire cohort was 26.2 per
10,000 person-years of follow-up. Multivariable analysis
adjusted for age, gender, race/ethnicity, diagnosis, treatment
era, HCT conditioning, and GvHD, revealed older age at HCT
(>40 yrs [RR¼5.9, P < .01]) and total body irradiation (TBI
[RR¼14.4, P ¼ .01]) to be independent risk factors for
cirrhosis. Five-year survival following diagnosis of cirrhosis
was 38.2% (primary cause of death: liver failure in 84.6%)
Conclusions: The incidence of cirrhosis increases with time
from HCT. While the risk is higher among those transplanted
before 1992, recent HCT recipients remain at increased risk.
Older age at HCT and conditioning with TBI signiﬁcantly
increase risk of cirrhosis. These data form the basis for
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Introduction: Children undergoing hematopoietic stem cell
transplantation (HSCT) are at risk of developing vitamin D
deﬁciency (VDD). However, data on vitamin D status and its
correlation with bone mineral density (BMD) in the long
term survivors after childhood HSCT is limited. The aim of
this study was to determine the prevalence of VDD among
long term survivors after HSCT in childhood, and to evaluate
the correlations between vitamin D and BMD.
Methods: A retrospective study was carried out in patients
seen in Long Term follow-up Clinic (LTFC) at our institution
from January 2011 to July 2012. VDD and insufﬁciency (VDI)
were deﬁned as serum 25-hydroxyvitamin D (25-OHD) <15
ng/mL and 15-30 ng/mL, respectively. BMD was measured
using dual-energy radiograph absorptiometry (Hologic Del-
phi). Lumbar, total body, and hip BMD Z scores were deter-
mined using manufacturer's normative data based on age.
Spearman's correlation was performed to assess correlation
between serum 25-OHD levels and different BMD variables.
Results: Ninety eight patients underwent 103 HSCTs
between 1990 and 2010. Fifty two (53%) patients were > 5
years out of transplant. A total of 114 vitamin D levels were
recorded for the 98 patients, the median 25-OHD level was
26 (range 7 - 68 ng/mL). In 68/114 (60%) observations the 25-
OHD levels were less than < 30ng/mL. Of these, 10 (9%)
patients had VDD (levels < 15ng/mL, while 58 (51%) had VDI.
There were no signiﬁcant correlations between 25-OHD
levels and age at HSCT, gender, underlying diagnosis, type of
transplant, or development of acute or chronic GVHD (Table
2). Therewas a trend towards lower 25-OHD levels after non-
TBI based conditioning regimen (P ¼ .047). BMD was per-
formed in 83 patients (85%). Low BMD was found in nearly
one-third to half of patients tested: 29%, 54%, and 33% of the
patients had BMDlumbar, BMDhip and BMDWB Z scores of<
-1.0, respectively, while 5%, 9% and 5% of the patients had
BMDlumbar, BMDhip and BMDWB Z scores < -2.5, respec-
tively. The median Z scores of the BMDlumbar, BMDhip, and
the BMDWB were -0.3 (range - 4.2 to 2.4), -1.1 (range -3.3 to
1.9), and -0.4 (range -5.4 to 2.7) respectively. In patients with
BMD < -2.5 and < -1.0, the corresponding median 25-OHD
was 26 (range 7 - 62 ng/mL) and there was no signiﬁcant
association. Spearman correlation between 25-OHD D level,
BMDWB and BMDlumbar showed a correlation coefﬁcient of
-0.24 (P value: 0.0409) and -0.22 (P value: 0.0546) respec-
tively. There was no correlation between normal vitamin D
levels, VDI and VDD with BMD of the hip, lumbar spine and
whole body.
Discussion: Low 25-OHD (<30 ng/mL) was common (60%) in
long term survivors after HSCT during childhood. Similar to
other reports, VDD and VDI was seen in 9%, and 51% of the
patients respectively. There was only a weak correlation of
the 25-OHD levels with BMD of whole body and the lumbar
spine, suggesting that factors other than hypovitaminosis D
might have contributed to low BMD. There was a small trend
of lower 25-OHD levels after non-TBI based conditioning.199
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Background: Consultation for abdominal pain (AP) in pedi-
atric patients following allogeneic hematopoietic stem cell
transplant (HSCT) is common. Non HSCT related GI inﬂam-
mation (infectious and non-infectious) has been associated
with post-inﬂammatory abdominal pain and functional
gastrointestinal disorders (FGID) in ashighas60%of cases. The
presence of AP and FGIDs after HSCT has not been described.
We hypothesized that AP is frequent after HSCT given the
inﬂammation from conditioning, GVHD and infection.
Methods: Patients >2 years from HSCT were offered
a Questionnaire of Pediatric Gastrointestinal Symptoms.
Thosewith active gut GVHDwere excluded. After completing
the surveys, chart reviews were performed focusing on
demographics, transplant characteristics, adverse events and
long-term outcomes.
Results: 48 patients completed the survey;7 (15%) had
abdominal complaints. 3 patients were diagnosed with AP
related FGID (dyspepsia, IBS, functional abdominal pain); 4
had AP that did not ﬁt criteria for diagnosis. The group with
AP were transplanted for high risk malignancy (71%) e
ALL(2), AML (1), Anaplastic Lymphoma (1) and Stage IV
Neuroblastoma(1). There was an increased incidence of total
body irradiation (TBI) containing regimens (57% vs 39%) in
patients with AP, but conditioning regimen intensity ie.
myeloablative versus reduced intensity (MA/RIC) was not
associated with AP. There was an increased incidence of
aGVHD (43.9% vs 29.3%), however surprisingly incidence of
GI aGVHD was equal between groups. Those with AP had
a higher incidence of second transplants (28.5% vs 4.9%),
which were performed for relapse. The AP group also had
more frequent abdominal infections (40% vs. 15%). The time
interval from HSCT in the AP/FGID group is shorter (4 years),
compared to the non-AP group (6 years), P ¼ .029; however
there were no other signiﬁcant demographic differences
between the two groups.
Conclusions: AP and FGIDs are common after HSCT in chil-
dren.APwasmore frequent inpatients<5yrs fromHSCT.Data
suggested that TBI, abdominal infections and relapse may be
associated with later development of abdominal pain. Larger
studies are needed for further evaluation and to conﬁrm these
ﬁnding. The investigation of post-HSCT AP and FGIDs may
help understand the role of inﬂammation, stress, coping and
families on the development of functional abdominal pain.
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